Table 2.
Ongoing/planned clinical trials for B-NHL.
| Phase | Sponsor | Clinical trial identifier | Condition | Concomitant medication | Primary end point |
|---|---|---|---|---|---|
| I | NCI | NCT02568553 | R/R B-NHL | Lenalidomide | MTD |
| I | Washington University School of Medicine | NCT03072771 | DLBCL post ASCT | BEAM ASCT | DLT/AE |
| Ib | Amgen | NCT02961881 | R/R indolent B-NHL | None | DLT/AE |
| Ib | Amgen | NCT03340766 | R/R DLBCL | Pembrolizumab | DLTs |
| II | Amgen | NCT02811679 | R/R indolent B-NHL | None | ORR |
| II | Amgen | NCT03023878 | High-risk DLBCL | Following up-front chemotherapy | Incidence/Severity AE |
| II | MDACC | NCT03121534 | Richter’s transformation | Dexamethasone | ORR |
| II | Amgen | NCT03298412 | MRD positive DLBCL post ASCT | None | MRD negativity |
| II/III | Amgen | NCT02910063 | R/R aggressive B-NHL | None vs. IC chemotherapy | CMR |
B-NHL: B-cell non Hodgkin lymphoma, DLBCL: diffuse large B-cell lymphoma; NCI: National Cancer Institute; MDACC: MD Anderson Cancer Centre; R/R: relapsed or refractory; MRD: minimal residual disease; IC: Investigator’s choice; ASCT: Autologous stem cell transplant; MTD: maximum tolerated dose; DLT: dose limiting toxicities; AE: adverse events ORR: overall response rate; CMR: complete metabolic response;